Major US health systems expect to offer Alzheimer's drug Leqembi in a few months
By Julie Steenhuysen and Deena Beasley CHICAGO Five major U.S. health systems said they would offer Eisai and
1970-01-01 08:00
Explainer-Who is eligible for the new FDA-approved Alzheimer's drug?
By Deena Beasley The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen's Leqembi for
1970-01-01 08:00
US FDA panel back traditional approval for Eisai-Biogen's Alzheimer's drug Leqembi
By Leroy Leo and Julie Steenhuysen A panel of expert advisers on Friday unanimously agreed that a late-stage
1970-01-01 08:00
Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 billion a year, study finds
(This May 11 story has been corrected to change some wording in the quote by Dr. Mafi in paragraph 15)
1970-01-01 08:00